241 related articles for article (PubMed ID: 17229074)
21. Biomarkers for PTLD diagnosis and therapies.
Martinez OM
Pediatr Nephrol; 2020 Jul; 35(7):1173-1181. PubMed ID: 31240394
[TBL] [Abstract][Full Text] [Related]
22. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy.
Nourse JP; Jones K; Gandhi MK
Am J Transplant; 2011 May; 11(5):888-95. PubMed ID: 21521464
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA
Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146
[TBL] [Abstract][Full Text] [Related]
25. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.
Choquet S; Varnous S; Deback C; Golmard JL; Leblond V
Am J Transplant; 2014 Apr; 14(4):857-66. PubMed ID: 24666832
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus (EBV) genotypes among human immunodeficiency virus (HIV)-related B-cell lymphomas and B-cell post-transplant lymphoproliferative disorders (B-PTLD)--late-onset lymphomas, especially in the HIV setting, are associated with type-B-EBV.
Ibrahim HA; Menasce LP; Pomplun S; Burke M; Bower M; Naresh KN
Eur J Haematol; 2010 Sep; 85(3):227-30. PubMed ID: 20408873
[TBL] [Abstract][Full Text] [Related]
27. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Mentzer SJ; Perrine SP; Faller DV
Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
[TBL] [Abstract][Full Text] [Related]
28. PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas.
Furukawa S; Wei L; Krams SM; Esquivel CO; Martinez OM
Am J Transplant; 2013 Aug; 13(8):2035-43. PubMed ID: 23841834
[TBL] [Abstract][Full Text] [Related]
29. Posttransplant Lymphoproliferative Disorder in Pediatric Patients: Characteristics of Disease in EBV-seropositive Recipients.
L'Huillier AG; Dipchand AI; Ng VL; Hebert D; Avitzur Y; Solomon M; Ngan BY; Yeung S; Stephens D; Punnett AS; Barton M; Allen UD
Transplantation; 2019 Nov; 103(11):e369-e374. PubMed ID: 31385930
[TBL] [Abstract][Full Text] [Related]
30. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
Zimmermann H; Oschlies I; Fink S; Pott C; Neumayer HH; Lehmkuhl H; Hauser IA; Dreyling M; Kneba M; Gärtner B; Anagnostopoulos I; Riess H; Klapper W; Trappe RU
Transplantation; 2012 Mar; 93(5):543-50. PubMed ID: 22234349
[TBL] [Abstract][Full Text] [Related]
31. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors.
White RE; Rämer PC; Naresh KN; Meixlsperger S; Pinaud L; Rooney C; Savoldo B; Coutinho R; Bödör C; Gribben J; Ibrahim HA; Bower M; Nourse JP; Gandhi MK; Middeldorp J; Cader FZ; Murray P; Münz C; Allday MJ
J Clin Invest; 2012 Apr; 122(4):1487-502. PubMed ID: 22406538
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy for Epstein-Barr virus-associated malignancies.
Long HM; Parsonage G; Fox CP; Lee SP
Drug News Perspect; 2010 May; 23(4):221-8. PubMed ID: 20520851
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus modulates host cell microRNA-194 to promote IL-10 production and B lymphoma cell survival.
Harris-Arnold A; Arnold CP; Schaffert S; Hatton O; Krams SM; Esquivel CO; Martinez OM
Am J Transplant; 2015 Nov; 15(11):2814-24. PubMed ID: 26147452
[TBL] [Abstract][Full Text] [Related]
34. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
[TBL] [Abstract][Full Text] [Related]
35. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment.
Petrara MR; Giunco S; Serraino D; Dolcetti R; De Rossi A
Cancer Lett; 2015 Dec; 369(1):37-44. PubMed ID: 26279520
[TBL] [Abstract][Full Text] [Related]
36. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
Peters AC; Akinwumi MS; Cervera C; Mabilangan C; Ghosh S; Lai R; Iafolla M; Doucette K; Preiksaitis JK
Transplantation; 2018 Sep; 102(9):1553-1562. PubMed ID: 29485513
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients.
Preiksaitis JK; Keay S
Clin Infect Dis; 2001 Jul; 33 Suppl 1():S38-46. PubMed ID: 11389521
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
San-Juan R; Comoli P; Caillard S; Moulin B; Hirsch HH; Meylan P;
Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus infection and altered control of apoptotic pathways in posttransplant lymphoproliferative disorders.
Ghigna MR; Reineke T; Rincé P; Schüffler P; El Mchichi B; Fabre M; Jacquemin E; Durrbach A; Samuel D; Joab I; Guettier C; Lucioni M; Paulli M; Tinguely M; Raphael M
Pathobiology; 2013; 80(2):53-9. PubMed ID: 22868923
[TBL] [Abstract][Full Text] [Related]
40. Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice.
Caduff N; McHugh D; Murer A; Rämer P; Raykova A; Landtwing V; Rieble L; Keller CW; Prummer M; Hoffmann L; Lam JKP; Chiang AKS; Raulf F; Azzi T; Berger C; Rubic-Schneider T; Traggiai E; Lünemann JD; Kammüller M; Münz C
PLoS Pathog; 2020 Apr; 16(4):e1008477. PubMed ID: 32251475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
